Titanovo Logo
Back to Cell Types

NCI-H2171Homo sapiens (Human)Cancer cell line

Also known as: NCIH2171, H-2171, H2171

🤖 AI SummaryBased on 15 publications

Quick Overview

Human small cell lung cancer cell line with known genetic alterations.

Detailed Summary

The NCI-H2171 cell line is a human small cell lung cancer (SCLC) cell line derived from a metastatic lesion. It is characterized by specific genetic alterations, including mutations in the TP53 gene and amplifications of the MYC family of oncogenes. These alterations are associated with aggressive tumor behavior and resistance to conventional therapies. The cell line is widely used in research to study the molecular mechanisms of SCLC and to develop targeted therapies. Its genetic profile makes it a valuable model for understanding the pathogenesis of small cell lung cancer and for testing new therapeutic strategies.

Research Applications

Molecular mechanisms of SCLCTargeted therapy developmentGenetic alteration analysis

Key Characteristics

TP53 mutationMYC family amplificationMetastatic origin
Generated on 6/17/2025

Basic Information

Database IDCVCL_1536
SpeciesHomo sapiens (Human)
Tissue SourcePleural effusion[UBERON:UBERON_0000175]

Donor Information

Age50
Age CategoryAdult
SexMale
Racecaucasian

Disease Information

DiseaseSmall cell lung cancer
LineageLung
SubtypeSmall Cell Lung Cancer
OncoTree CodeSCLC

DepMap Information

Source TypeATCC
Source IDACH-000525_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Gln144Ter (c.430C>T)Heterozygous-PubMed=29970484, PubMed=11799138, PubMed=8782485, PubMed=8725545
MutationSimpleRB1p.Ser567Ter (c.1700C>A)Homozygous-Unknown, Unknown, Unknown
Gene fusionPVT1PVT1-SLC7A7--PubMed=23716474
Gene fusionCHD7PVT1-CHD7--PubMed=23716474, PubMed=18438408
Gene fusionCCNB1IP1PVT1-CCNB1IP1--PubMed=23716474
Gene fusionCACNA2D4CACNA2D4-WDR43-Out of framePubMed=18438408

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
10
D13S317
11
D16S539
12,13
D18S51
18
D19S433
16
D21S11
28,32.2
D2S1338
16,20
D3S1358
15
D5S818
13
D7S820
11,13
D8S1179
12
FGA
22
Penta D
12
Penta E
10
TH01
9.3
TPOX
8
vWA
17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.

Gerstberger T., Zuber J., Savarese F., Kraut N.

Oncogene 37:2687-2701(2018).

DOIPubMedPMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

DOIPubMedPMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOIPubMed

Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer.

Yokota J.

Genes Chromosomes Cancer 52:802-816(2013).

DOIPubMedPMC

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

DOIPubMedPMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

Lung cancer cell lines as tools for biomedical discovery and research.

Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.

J. Natl. Cancer Inst. 102:1310-1321(2010).

DOIPubMedPMC

MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs.

Gazdar A.F., Pertsemlidis A.

J. Exp. Clin. Cancer Res. 29:75.1-75.12(2010).

DOIPubMedPMC

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Cancer Sci. 101:1891-1896(2010).

DOIPubMedPMC

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOIPubMedPMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOIPubMedPMC

A gene-alteration profile of human lung cancer cell lines.";

Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

Hum. Mutat. 30:1199-1206(2009).

DOIPubMedPMC

Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing.

Bignell G.R., Stratton M.R., Futreal P.A.

Nat. Genet. 40:722-729(2008).

DOIPubMedPMC

Chromosome abnormalities in 10 lung cancer cell lines of the NCI-H series analyzed with spectral karyotyping.

Grigorova M., Lyman R.C., Caldas C., Edwards P.A.W.

Cancer Genet. Cytogenet. 162:1-9(2005).

DOIPubMed

High-resolution analysis of DNA copy number using oligonucleotide microarrays.

Weber B., Shapero M.H., Wooster R.

Genome Res. 14:287-295(2004).

DOIPubMedPMC

Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.

Minna J.D.

Oncogene 20:1005-1009(2001).

DOIPubMed

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

DOIPubMed

Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering.

Girard L., Zochbauer-Muller S., Virmani A.K., Gazdar A.F., Minna J.D.

Cancer Res. 60:4894-4906(2000).

PubMed

Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types.

Minna J.D., Gazdar A.F.

Genes Chromosomes Cancer 21:308-319(1998).

DOIPubMed

MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer.

Ihde D.C., Gazdar A.F.

J. Cell. Biochem. Suppl. 24:210-217(1996).

DOIPubMed

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

DOIPubMed

Web Resources

cellosaurus.org